Taxanes Versus Androgen Receptor Therapy as Second-Line Treatment for Castrate-Resistant Metastatic Prostate Cancer...

Area of Science:

• Oncology
• Medical Research

Background:

• The optimal treatment sequence for metastatic castrate-resistant prostate cancer (mCRPC) remains a critical clinical question.
• Androgen-receptor therapy (ART) and taxanes (TAX) are key treatment modalities in mCRPC management.

Purpose of the Study:

• To compare the efficacy of taxanes (TAX) versus androgen-receptor therapy (ART) as second-line treatment in patients with mCRPC who have previously received first-line ART.
• To evaluate progression-free survival (PFS) and overall survival (OS) based on second-line treatment choice.

Main Methods:

• Retrospective analysis of chemo-naive mCRPC patients who received first-line ART (enzalutamide or abiraterone).
• Comparison of outcomes between patients receiving second-line TAX or ART.
• Propensity score adjustment was used to control for confounding factors.

Main Results:

• Second-line taxanes (TAX) demonstrated significantly higher prostate-specific antigen (PSA) and radiological response rates compared to second-line ART (29% vs. 0% and 21% vs. 0%, respectively).
• While PFS was longer with second-line TAX (6.7 months) versus ART (4 months), overall survival (OS) did not differ significantly between the groups (19 months vs. 12 months).
• After propensity score adjustment, no significant differences in PFS or OS were observed between second-line TAX and ART.

Conclusions:

• Second-line taxanes offer superior objective response rates (PSA and radiological) compared to continued ART in mCRPC patients post-first-line ART.
• Despite higher response rates, second-line taxanes do not significantly improve overall survival compared to second-line ART in this patient population.
• The findings provide valuable insights for sequencing therapies in mCRPC, suggesting that while TAX may offer better initial responses, the long-term survival benefit over ART is not definitively established in this context.